Insulin glargine (Basaglar) vs Insulin glargine (Toujeo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin glargine (Basaglar)
Marketed by Eli Lilly and partners
NCT01421459 · Phase 3 · completed
The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)
Result source: NCT03338010
Insulin glargine (Toujeo)
Marketed by Sanofi
NCT01499082 · Phase 3 · completed
The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.
Reported efficacy
Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)
Result source: NCT01499082
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin glargine (Basaglar) | Insulin glargine (Toujeo) |
|---|---|---|
| HbA1c, change | -1.3% vs -1.3%vs LantusNCT014214599 other results
| —Not reported |
| Body weight, change (kg) | 1.9 vs 2.2vs LantusNCT014214597 other results
| —Not reported |
| HbA1c below 7% | 43.7% vs 44.9%vs Lantus®NCT03338010 | —Not reported |
| Fasting plasma glucose, change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- Insulin glargine (Basaglar)
- -1.3% vs -1.3%vs LantusNCT01421459
9 other results
- -1.3% vs -1.2% NCT02302716
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.3% NCT01421459
- -1.1% vs -1.1% NCT01421459
- -0.9% vs -0.9% NCT01421459
- -0.5% vs -0.5% NCT01421459
- Insulin glargine (Toujeo)
- —Not reported
Body weight, change (kg)
- Insulin glargine (Basaglar)
- 1.9 vs 2.2vs LantusNCT01421459
7 other results
- 2.3 vs 1.7 NCT02302716
- 1.1 vs 1.2 NCT03338010
- 1.7 vs 2.2 NCT01421459
- 1.6 vs 1.9 NCT01421459
- 1.3 vs 1.4 NCT01421459
- 1.0 vs 1.2 NCT01421459
- 0.3 vs 0.5 NCT01421459
- Insulin glargine (Toujeo)
- —Not reported
HbA1c below 7%
- Insulin glargine (Basaglar)
- 43.7% vs 44.9%vs Lantus®NCT03338010
- Insulin glargine (Toujeo)
- —Not reported
Fasting plasma glucose, change
- Insulin glargine (Basaglar)
- —Not reported
- Insulin glargine (Toujeo)
- —Not reported
3-point MACE (% with event)
- Insulin glargine (Basaglar)
- —Not reported
- Insulin glargine (Toujeo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Insulin glargine (Basaglar): 6 of 6 rows · Insulin glargine (Toujeo): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin glargine (Basaglar) | Insulin glargine (Toujeo) |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.86% (n=259) @ 24wka,b,c NCT04153981 · Phase 4 · registry result, not featured evidence | -1.29% (n=1651) @ 52wka,b,c NCT02451137 · Phase 4 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -0.5 kg @ 24wka,b,c NCT04153981 · Phase 4 · registry result, not featured evidence | 1.51 kg @ 52wka,b,c NCT02451137 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 11.9%d NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results7.6% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.4% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence | 14.8%e NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result14.9% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 1.6%d NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results0.4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT04153981 · Phase 4 · registry result, not featured evidence | —e NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result2.6% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 4%d NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence | 19.4%e NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result9.8% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | d nasopharyngitis 5.6% upper respiratory tract infection 5.1% abnormal weight gain 2.7% NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more resultsnasopharyngitis 7.2% upper respiratory tract infection 4% weight increased 3.2% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 upper respiratory tract infection 20.3% hypertension 5.6% injection site pain 4.2% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence | e trauma 3.7% cough 0.9% gastroparesis 0.9% NCT03013985 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 24 weeks versus 52 weeks.
- dPopulation comparability has not been reviewed for 1 of these studies.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin glargine (Basaglar)
show 9 more results
show 7 more results
Insulin glargine (Toujeo)
show 6 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Basaglar)'s landscape · Insulin glargine (Toujeo)'s landscape